Table 4

Doxorubicin and doxorubicinol concentrations in plasma and breast tissue. A value of “0” was noted for concentrations below the limits of quantification of the analytical assay. NA, not applicable; NC, specimen not collected. id, intraductal; iv, intravenous.

PLD dose (mg),
route of
administration
SubjectDays
to
surgery
Doxorubicin/doxorubicinol
(nM) in plasma
Doxorubicin/doxorubicinol
(nmol/g) in breast tissue
0
hours
4
hours
24
hours
8
days
Day of
surgery
Blue-dyed
region
Non–blue-dyed
region
Contralateral
breast*
0, id (dextrose)0015NCNCNCNCNC0/00/0NC
0025NCNCNCNCNC0/00/0NC
00323NCNCNCNCNC0/00/0NC
2, id101170/00/00/00/00/00/00/0NC
102130/028.5/00/00/00/00/00/00/0
104400/00/00/0NC0/00/00/00/0
5, id202200/00/00/00/00/00/00/00/0
203120/018.3/00/00/00/00/00/00/0
204100/00/00/00/00/01.73/0.090/00/0
10, id30190/00/00/00/00/00.42/04.58/0.21NC
302120/0132.0/0481.0/22.6134.0/011.3/00.07/00.07/00/0
30370/024.4/0480.0/22.6NC902.0/36.91.23/0.051.00/0.040/0
304180/00/00/00/00/00.11/00/0NC
305130/00/060.9/00/00/00.24/010.82/5.26NC
306180/00/087.3/0346/17.854.5/02.86/0.160.71/0.04NC
68, iv40180/065,900/8,09079,600/3,190NC28,400/869NANA0/0
80, iv402130/055,100/4,00033,700/1,9802,760/294163/11NANA0/0
68, iv403210/041,300/2,26044,400/2,48018,300/286228/16NANA0.21/0

*Specimens were obtained for baseline doxorubicin measures as a control and because of previous doxorubicin exposure in some women.

†40 mg/m2.